Qiagen STI assay cleared for use on NeuMoDx systems

February 2024—Qiagen announced FDA clearance of the NeuMoDx CT/NG assay 2.0 for its NeuMoDx 96 and 288 integrated PCR-based clinical molecular testing systems in the United States. The assay is designed for direct detection of asymptomatic and symptomatic bacterial infections for *Chlamydia trachomatis* and *Neisseria gonorrhoeae*. Results are delivered in about an hour.

Qiagen says this clearance supports its test menu expansion for NeuMoDx systems in the U.S. and builds on the 16 EU-certified in vitro diagnostic tests available on these systems, including assays for transplant-associated viruses, respiratory infections, blood-borne viruses, and sexual and reproductive health.

Qiagen, 240-686-7700